Asunto(s)
Autoanticuerpos/sangre , Diabetes Mellitus Tipo 1/congénito , Diarrea/sangre , Enfermedades Genéticas Ligadas al Cromosoma X/sangre , Enfermedades del Sistema Inmune/congénito , Síndrome de Isaacs/sangre , Canales de Potasio con Entrada de Voltaje/inmunología , Adolescente , Niño , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/genética , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/terapia , Diarrea/genética , Diarrea/inmunología , Diarrea/terapia , Factores de Transcripción Forkhead/genética , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Enfermedades Genéticas Ligadas al Cromosoma X/inmunología , Enfermedades Genéticas Ligadas al Cromosoma X/terapia , Trasplante de Células Madre Hematopoyéticas , Humanos , Enfermedades del Sistema Inmune/sangre , Enfermedades del Sistema Inmune/genética , Enfermedades del Sistema Inmune/inmunología , Enfermedades del Sistema Inmune/terapia , Recién Nacido , Síndrome de Isaacs/genética , Síndrome de Isaacs/inmunología , Síndrome de Isaacs/terapia , Masculino , MutaciónAsunto(s)
Síndrome de Isaacs/diagnóstico , Remisión Espontánea , Adolescente , Alanina Transaminasa/análisis , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/análisis , Aspartato Aminotransferasas/sangre , Creatina Quinasa/análisis , Creatina Quinasa/sangre , Humanos , Síndrome de Isaacs/sangre , Síndrome de Isaacs/complicaciones , Masculino , Calambre Muscular/etiología , Dolor/etiología , Pérdida de Peso/fisiologíaRESUMEN
Importance: Although acquired autoimmune neuromyotonia (NMT) is associated with voltage-gated potassium channel (VGKC)-complex antibodies, to date there has been no systematic study of autoantibodies to the specific antigens leucine-rich glioma inactivated protein 1 (LGI1), contactin-associated protein 2 (CASPR2), and contactin 2 together with the full clinical syndrome, particularly pain and autonomic and central nervous system involvement. Objectives: To study the full spectrum of clinical features and serum autoantibodies in patients with NMT, including the effects of pain on quality of life. Design, Setting, and Participants: A cohort study of clinical features and serologic testing in 38 patients with electrophysiologically-confirmed NMT, reviewed clinically between February 2007 and August 2009, in the Universities of Sydney and Kagoshima and followed up across 2 to 4 years. Association of NMT with quality of life was researched in an independent, patient-led, online pain survey conducted from April 2012 to May 2012. Serologic analyses were performed in 2012, and final data analysis was performed in 2016. Main Outcomes and Measures: Clinical data and scores on the modified Rankin Scale (mRS), which measures disability on a range of 0 to 6, with 0 indicating normal and 6 indicating death, before and after treatments were combined with CASPR2, LGI1, and contactin 2 antibody status. Results: Among the 38-person NMT cohort, 25 (65.8%) were male and the median (range) age was 55 (12-85) years. Twenty-three (60.5%) were Japanese and 15 (39.5%) were of white race/ethnicity. Symptomatic treatments (mainly antiepileptic drugs) were used in most patients with mild disease (12 patients with mRS <3), whereas immunotherapies were successful in most patients with mRS scores greater than 2. Autoantibodies to VGKC-complex antigens (17 patients [45%]), bound to CASPR2 (5 [13%]), contactin 2 (5 patients, 1 with CASPR2 [13%]), LGI1 (2 [5%]), or both LGI1 and CASPR2 (6 [16%]). The last group of 6 patients had high mRS scores (mean [SD], 3.8 [1.7]), thymoma (4 patients), pain (5 patients), autonomic (6 patients) and sleep (5 patients) disturbance, suggesting Morvan syndrome. The 56 responders to the independent patient-led survey reported pain that could be severe, anatomically widespread, and that often resulted in unemployment, domestic problems, and poor quality of life. Conclusions and Relevance: The cohort study detailed underrecognized aspects of the clinical and serologic spectrum of NMT. The heterogeneity of clinical features and of specific antibodies limit associations, but the common existence of thymoma, pain, and autonomic and central nervous system features, often with both LGI1 and CASPR2 antibodies, should be better recognized to more completely address the range of comorbidities and consequences of the disease regarding quality of life.
Asunto(s)
Autoanticuerpos/sangre , Contactina 2/inmunología , Síndrome de Isaacs , Proteínas de la Membrana/inmunología , Proteínas del Tejido Nervioso/inmunología , Dolor/fisiopatología , Medición de Resultados Informados por el Paciente , Proteínas/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Estudios de Cohortes , Femenino , Humanos , Péptidos y Proteínas de Señalización Intracelular , Síndrome de Isaacs/sangre , Síndrome de Isaacs/complicaciones , Síndrome de Isaacs/inmunología , Síndrome de Isaacs/fisiopatología , Masculino , Persona de Mediana Edad , Calidad de Vida , Adulto JovenRESUMEN
Isaacs syndrome is a form of peripheral nerve hyperexcitability, characterized by spontaneous muscle twitching and stiffness. Some patients are reported to be positive for CASPR2 antibody that may be one of the pathogenic autoantibodies in Isaacs syndrome. We reported a series of three patients with Isaacs syndrome, including their clinical features, electrophysiologic findings, laboratory parameters and therapeutic responses. All the three patients were positive for CASPR2 antibodies examined on transfected human embryonic kidney 293 cells by indirect immunofluorescence method. One patient had invasive thymoma. Symptomatic treatment was not sufficient for them, while immunotherapies including corticosteroids, double filtration plasmapheresis and rituximab provided favorable outcomes. The titers of CASPR2 antibody decreased after immune modulating therapy in parallel to clinical improvements in two patients.
Asunto(s)
Autoanticuerpos/inmunología , Síndrome de Isaacs/diagnóstico , Proteínas de la Membrana/inmunología , Proteínas del Tejido Nervioso/inmunología , Adulto , Femenino , Humanos , Síndrome de Isaacs/sangre , Síndrome de Isaacs/tratamiento farmacológico , Síndrome de Isaacs/inmunología , Masculino , Persona de Mediana EdadAsunto(s)
Hemofilia A/complicaciones , Síndrome de Isaacs/complicaciones , Miastenia Gravis/complicaciones , Anciano , Autoanticuerpos/sangre , Hemofilia A/sangre , Humanos , Síndrome de Isaacs/sangre , Masculino , Miastenia Gravis/sangre , Canales de Potasio con Entrada de Voltaje/inmunología , Receptores Colinérgicos/inmunologíaAsunto(s)
Anticuerpos Antineoplásicos/sangre , Anticuerpos/sangre , Síndrome de Isaacs/sangre , Timoma/sangre , Anticuerpos Antinucleares , Encéfalo/diagnóstico por imagen , Encéfalo/patología , Humanos , Síndrome de Isaacs/complicaciones , Masculino , Persona de Mediana Edad , Radiografía Torácica , Timoma/complicaciones , Tomógrafos Computarizados por Rayos XRESUMEN
Autoimmune ion channel disorders of the peripheral nervous system include myasthenia gravis, the Lambert-Eaton myasthenic syndrome, acquired neuromyotonia and autoimmune autonomic ganglionopathies. These disorders are characterized by the common feature of being mediated by IgG autoantibodies against identified target antigens, i.e. the acetylcholine receptor, the voltage-gated calcium and potassium channels, and the neuronal acetylcholine receptor. Moreover, experimental animal models have been identified for these diseases that respond to immunotherapy and are improved by plasmapheresis. On this basis, autoimmune ion channel disorders represent the ideal candidate for therapeutic apheresis. Immunoadsorption can be the treatment of choice when intensive apheretic protocols or long-term treatments must be performed, in patients needing frequent apheresis to keep a stable clinical condition, in case of unresponsiveness to corticosteroids and immunosuppressive treatments, or failure with TPE or intravenous immunoglobulins, and in patients with severe contraindications to long-term corticosteroids.
Asunto(s)
Autoanticuerpos/sangre , Enfermedades Autoinmunes del Sistema Nervioso/terapia , Autoinmunidad , Eliminación de Componentes Sanguíneos/métodos , Técnicas de Inmunoadsorción , Inmunoadsorbentes/uso terapéutico , Canales Iónicos/inmunología , Enfermedades del Sistema Nervioso Periférico/terapia , Adsorción , Enfermedades Autoinmunes del Sistema Nervioso/sangre , Enfermedades Autoinmunes del Sistema Nervioso/diagnóstico , Enfermedades Autoinmunes del Sistema Nervioso/inmunología , Enfermedades del Sistema Nervioso Autónomo/sangre , Enfermedades del Sistema Nervioso Autónomo/inmunología , Enfermedades del Sistema Nervioso Autónomo/terapia , Biomarcadores/sangre , Humanos , Inmunoglobulina G/sangre , Síndrome de Isaacs/sangre , Síndrome de Isaacs/inmunología , Síndrome de Isaacs/terapia , Síndrome Miasténico de Lambert-Eaton/sangre , Síndrome Miasténico de Lambert-Eaton/inmunología , Síndrome Miasténico de Lambert-Eaton/terapia , Miastenia Gravis/sangre , Miastenia Gravis/inmunología , Miastenia Gravis/terapia , Enfermedades del Sistema Nervioso Periférico/sangre , Enfermedades del Sistema Nervioso Periférico/diagnóstico , Enfermedades del Sistema Nervioso Periférico/inmunología , Resultado del TratamientoRESUMEN
OBJECTIVE: Isaacs' syndrome is a rare disease resulting from hyperexcitability of peripheral nerves causing continuous muscle fiber activity characterized by muscle twitching and stiffness at rest and delayed muscle relaxation after voluntary contraction. Our objective was to discuss the relationship of Isaacs' syndrome to paraneoplastic syndromes as reported in the available literature and in 3 patients evaluated at our academic medical center. METHODS: We review the literature on Isaacs' syndrome and describe 3 patients in whom Isaacs' syndrome heralded underlying malignancy or benign neoplasm, including their presenting symptoms, electrophysiologic findings, and laboratory and pathology results. RESULTS: In all 3 cases, clinical and electrodiagnostic testing was suggestive of Isaacs' syndrome. Two patients tested positive, and one was negative for voltage-gated potassium channel antibodies. Two of the patients developed malignant tumors, that is, one was diagnosed with metastatic thymoma and one with lymphoplasmacytic lymphoma, ranging from 6 months to 1 year after the diagnosis of Isaacs' syndrome. One patient was diagnosed with a spinal cord hemangioblastoma 5 years after he was diagnosed with Isaacs' syndrome. CONCLUSIONS: Our case series highlights the association of Isaacs' syndrome with a variety of neoplasms both malignant and benign. Our report also underscores the fact that Isaacs' syndrome may be diagnosed several years before a neoplasm is discovered. In our cases, Isaacs' syndrome overlapped with other neuromuscular disorders, that is, myasthenia gravis in a patient with thymoma and chronic inflammatory demyelinating polyneuropathy in a patient with lymphoplasmacytic lymphoma with paraproteinemia. To our knowledge, this is the first report of an association between Isaacs' syndrome with lymphoplasmacytic lymphoma and a spinal cord hemangioblastoma.
Asunto(s)
Síndrome de Isaacs/diagnóstico , Síndrome de Isaacs/fisiopatología , Autoanticuerpos , Electromiografía , Fasciculación/etiología , Humanos , Síndrome de Isaacs/sangre , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Músculo Esquelético/patología , Músculo Esquelético/fisiopatología , Tomografía de Emisión de Positrones , Canales de Potasio con Entrada de Voltaje/inmunologíaRESUMEN
Neuromyotonia is a heterogeneous group of genetic and autoimmune channelopathies resulting in hyperexcitability of peripheral nerves. We report an unusual case of neuromyotonia, which to our knowledge has not been previously described. The patient developed intermittent attacks of severe painful muscle stiffness accompanied by sweating, myokymia and raised serum creatine kinase. Genetic analysis of KCNA1, KCNQ2 and SCN4A genes did not identify pathogenic mutation. Serum voltage-gated potassium channel antibody was also negative. He was successfully treated with acetazolamide and carbamazepine. This appears to be a new neuromuscular disease, "paroxysmal neuromyotonia", the etiology of which is still unknown.
Asunto(s)
Síndrome de Isaacs/diagnóstico , Miocimia/diagnóstico , Creatina Quinasa/sangre , Electromiografía , Humanos , Síndrome de Isaacs/sangre , Síndrome de Isaacs/fisiopatología , Masculino , Persona de Mediana Edad , Músculo Esquelético/fisiopatología , Miocimia/sangre , Miocimia/fisiopatología , Conducción Nerviosa/fisiología , Sudoración/fisiologíaRESUMEN
Antibodies that immunoprecipitate (125)I-alpha-dendrotoxin-labelled voltage-gated potassium channels extracted from mammalian brain tissue have been identified in patients with neuromyotonia, Morvan's syndrome, limbic encephalitis and a few cases of adult-onset epilepsy. These conditions often improve following immunomodulatory therapies. However, the proportions of the different syndromes, the numbers with associated tumours and the relationships with potassium channel subunit antibody specificities have been unclear. We documented the clinical phenotype and tumour associations in 96 potassium channel antibody positive patients (titres >400 pM). Five had thymomas and one had an endometrial adenocarcinoma. To define the antibody specificities, we looked for binding of serum antibodies and their effects on potassium channel currents using human embryonic kidney cells expressing the potassium channel subunits. Surprisingly, only three of the patients had antibodies directed against the potassium channel subunits. By contrast, we found antibodies to three proteins that are complexed with (125)I-alpha-dendrotoxin-labelled potassium channels in brain extracts: (i) contactin-associated protein-2 that is localized at the juxtaparanodes in myelinated axons; (ii) leucine-rich, glioma inactivated 1 protein that is most strongly expressed in the hippocampus; and (iii) Tag-1/contactin-2 that associates with contactin-associated protein-2. Antibodies to Kv1 subunits were found in three sera, to contactin-associated protein-2 in 19 sera, to leucine-rich, glioma inactivated 1 protein in 55 sera and to contactin-2 in five sera, four of which were also positive for the other antibodies. The remaining 18 sera were negative for potassium channel subunits and associated proteins by the methods employed. Of the 19 patients with contactin-associated protein-antibody-2, 10 had neuromyotonia or Morvan's syndrome, compared with only 3 of the 55 leucine-rich, glioma inactivated 1 protein-antibody positive patients (P < 0.0001), who predominantly had limbic encephalitis. The responses to immunomodulatory therapies, defined by changes in modified Rankin scores, were good except in the patients with tumours, who all had contactin-associated-2 protein antibodies. This study confirms that the majority of patients with high potassium channel antibodies have limbic encephalitis without tumours. The identification of leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 as the major targets of potassium channel antibodies, and their associations with different clinical features, begins to explain the diversity of these syndromes; furthermore, detection of contactin-associated protein-2 antibodies should help identify the risk of an underlying tumour and a poor prognosis in future patients.
Asunto(s)
Anticuerpos/sangre , Síndrome de Isaacs/sangre , Encefalitis Límbica/sangre , Proteínas de la Membrana/inmunología , Proteínas del Tejido Nervioso/inmunología , Canales de Potasio de la Superfamilia Shaker/inmunología , Siringomielia/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos/farmacología , Especificidad de Anticuerpos/inmunología , Línea Celular Transformada , Venenos Elapídicos/farmacocinética , Femenino , Regulación de la Expresión Génica/genética , Proteínas Fluorescentes Verdes/genética , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Humanos , Inmunoprecipitación/métodos , Inmunoterapia/métodos , Péptidos y Proteínas de Señalización Intracelular , Isótopos de Yodo/farmacocinética , Síndrome de Isaacs/tratamiento farmacológico , Síndrome de Isaacs/inmunología , Encefalitis Límbica/tratamiento farmacológico , Encefalitis Límbica/inmunología , Encefalitis Límbica/patología , Masculino , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/genética , Persona de Mediana Edad , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/fisiología , Técnicas de Placa-Clamp/métodos , Unión Proteica/efectos de los fármacos , Unión Proteica/fisiología , Proteínas , Índice de Severidad de la Enfermedad , Siringomielia/tratamiento farmacológico , Siringomielia/inmunología , Transfección/métodos , Resultado del Tratamiento , Adulto JovenAsunto(s)
Síndrome de Isaacs/diagnóstico , Miastenia Gravis/diagnóstico , Timoma/diagnóstico , Neoplasias del Timo/diagnóstico , Autoanticuerpos/sangre , Electromiografía , Humanos , Síndrome de Isaacs/sangre , Síndrome de Isaacs/complicaciones , Masculino , Persona de Mediana Edad , Miastenia Gravis/sangre , Miastenia Gravis/complicaciones , Timoma/sangre , Timoma/complicaciones , Neoplasias del Timo/sangre , Neoplasias del Timo/complicacionesRESUMEN
Isaac's syndrome is a movement disorder characterized by hyperexcitability of peripheral motor nerves. Patients with Isaac's syndrome often develop auto-antibodies to voltage-gated potassium channels (VGKCs) which block their function. However, anti-VGKC antibodies are not detected in all patients with Isaac's syndrome, suggesting the existence of another etiology. In this study, we performed immunoscreening using the serum from a patient with Isaac's syndrome and identified the novel gene named Kenae/CCDC125. Expression analysis of Kenae/CCDC125 revealed that its transcript was highly expressed in tissues associated with the immune system, such as the thymus, spleen and bone marrow. In cells stably expressing Kenae/CCDC125, delay in cell motility and deregulation of RhoGTPase (RhoA, Rac1 and cdc42) activity to extracellular stimuli were demonstrated. These results suggest that the novel gene, Kenae/CCDC125, acts as a regulator of cell motility through RhoA, Rac1 and cdc42.
Asunto(s)
Movimiento Celular , Proteínas Activadoras de GTPasa/metabolismo , Proteínas/metabolismo , Secuencia de Aminoácidos , Animales , Antígenos/sangre , Secuencia de Bases , Línea Celular Tumoral , Clonación Molecular , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Humanos , Síndrome de Isaacs/sangre , Síndrome de Isaacs/metabolismo , Ratones , Datos de Secuencia Molecular , Proteínas/química , Proteínas/genética , ARN Mensajero/genética , ARN Mensajero/metabolismoRESUMEN
Acquired neuromyotonia, or Isaacs' syndrome, has been described in combination with a variety of other autoimmune disorders; however there has never been a report of seropositive Isaacs' syndrome in a patient with a history of Guillain-Barré syndrome (GBS). Both conditions involve antibody-mediated autoimmune effects on the peripheral nervous system, although the clinical manifestations are quite different. We present a man who experienced an episode of GBS at the age of 21 and subsequently developed Isaacs' syndrome at the age of 24 which was positive for anti-voltage-gated potassium channel (VGKC) antibodies. When treated with intravenous immunoglobulins (IVIg) he developed an eczematous rash that differed markedly in pattern and duration from the usual presentation for this IVIg reaction.
Asunto(s)
Autoanticuerpos/sangre , Eccema/inducido químicamente , Síndrome de Guillain-Barré/complicaciones , Inmunoglobulinas Intravenosas/efectos adversos , Síndrome de Isaacs/inmunología , Canales de Potasio con Entrada de Voltaje/inmunología , Anticonvulsivantes/uso terapéutico , Autoanticuerpos/análisis , Agonistas de Dopamina/uso terapéutico , Eccema/inmunología , Eccema/fisiopatología , Exantema/inducido químicamente , Exantema/inmunología , Exantema/fisiopatología , Síndrome de Guillain-Barré/fisiopatología , Humanos , Enfermedad Iatrogénica , Factores Inmunológicos/efectos adversos , Síndrome de Isaacs/sangre , Síndrome de Isaacs/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Neuronas Motoras/inmunología , Neuronas Motoras/metabolismo , Neuronas Motoras/patología , Músculo Esquelético/inmunología , Músculo Esquelético/fisiopatología , Parálisis/etiología , Nervios Periféricos/efectos de los fármacos , Nervios Periféricos/inmunología , Nervios Periféricos/fisiopatología , Espasmo/inmunología , Espasmo/fisiopatología , Toxoide Tetánico/efectos adversosRESUMEN
Neuromyotonia or Isaacs' syndrome is a rare peripheral nerve hyperexcitability disorder caused by antibodies against potassium channels of myelinated axons. We present the high-density surface electromyographic (EMG) recordings of a patient with fasciculations and cramps due to neuromyotonia. To characterize the time course of hyperexcitability, we analyzed the interspike intervals (ISIs) between fasciculation potentials, doublet, and multiplet discharges. ISI duration increased within each burst. The ISI histograms found can be explained by the recovery cycle of the myelinated axon and its dependency on the slow potassium conductance. We conclude that ISI analysis is a useful tool to understand the membrane dynamics underlying abnormal motor unit activity.
Asunto(s)
Potenciales de Acción/fisiología , Anticuerpos/sangre , Síndrome de Isaacs , Canales de Potasio/inmunología , Potenciales de Acción/efectos de la radiación , Anciano , Estimulación Eléctrica , Electromiografía/métodos , Femenino , Humanos , Síndrome de Isaacs/sangre , Síndrome de Isaacs/inmunología , Síndrome de Isaacs/fisiopatologíaRESUMEN
Neuromuscular hyperexcitability is a characteristic of Isaacs' syndrome. Autoantibodies specific for voltage-gated potassium channels (VGKC) or ganglionic nicotinic acetylcholine receptors (AChR) are markers of this disorder. To determine the frequency of these ion channel antibodies and of related neuron- and muscle-specific antibodies in patients with acquired neuromuscular hyperexcitability, we tested serum specimens from 77 affected patients (35 neuromyotonia, 32 cramp-fasciculation syndrome, 5 rippling muscle syndrome, and 5 focal neuromuscular hyperexcitability) and 85 control subjects. Among study patients, 14% had coexisting myasthenia gravis, and 16% had an associated neoplasm. We found that 35% had VGKC antibodies, 12% ganglionic AChR antibodies, 16% muscle AChR antibodies, and 10% striational antibodies. Overall, 55% had serological evidence of neurological autoimmunity compared to 2% of control subjects. Patients with neuromyotonia were more frequently seropositive (71%) than patients with cramp-fasciculation syndrome (31%). We conclude that acquired neuromuscular hyperexcitability consists of a continuum of clinical disorders with a common autoimmune pathogenesis.